TOP TIERMARKET NEWSWIRE

News & sentiment

VivoSim Labs, Inc. (VIVS) — News & AI sentiment

VivoSim Labs, Inc. (VIVS) news roundup. 2 stories in the past week, 5 over 30 days. Average 30-day sentiment is 56.6/100. Recent insider activity (SEC Form 4, 90-day window): 1 purchases totalling $3K and 0 sales totalling $0 — net buying of $3K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

2

avg sentiment 56/100

30d stories

5

avg sentiment 56.6/100

Insider net (90d)

$3K

1 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

VIVS news in the last 24 hours, 7 days, 30 days and 90 days

How much VIVS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	VIVS stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	2	56/100	VIVS headlines →
Last 30 days	5	56.6/100	VIVS headlines →
Last 90 days	15	56.7/100	VIVS headlines →

Latest stories on VIVS

VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting

Business Insider56 · neutralproduct/pr

3d ago

VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting

GlobeNewswire56 · neutralproduct/pr

3d ago

VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test

Business Insider63 · neutralproduct/pr

Nov 3

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Business Insider58 · neutralproduct/pr

Oct 21

VivoSim Labs, INC. (VIVS) files 8-K

SEC 8-K50 · neutralgeneral

Oct 16

VivoSim celebrates updated FDA regulations in non-animal testing methods

The Fly63 · neutralproduct/pr

Oct 7

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

Business Insider67 · bullishproduct/pr

Oct 7

VivoSim Labs, INC. (VIVS) files 8-K

SEC 8-K50 · neutralgeneral

Oct 6

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

GlobeNewswire67 · bullishproduct/pr

Sep 16

VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs

Business Insider63 · neutralproduct/pr

Sep 16

VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity

Barchart63 · neutralproduct/pr

Sep 2

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

Business Insider63 · neutralproduct/pr

Sep 1

VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum

Barchart63 · neutralproduct/pr

Aug 25

VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency

TipRanks34 · bearishgeneral

Aug 21

VivoSim Labs, INC. (VIVS) files 8-K

SEC 8-K34 · bearishgeneral

Aug 21

VivoSim regains compliance with Nasdaq

The Fly59 · neutralgeneral

Aug 6

VivoSim Labs, INC. (VIVS) files 8-K

SEC 8-K50 · neutralgeneral

Aug 6

VivoSim Provides Financial and Listing Compliance Update

StockTitan63 · neutralgeneral

Aug 6

VivoSim Labs, INC. (VIVS) files 8-K

SEC 8-K50 · neutralgeneral

Jul 30

VivoSim Labs, INC. (VIVS) files 8-K

SEC 8-K34 · bearishgeneral

Jul 24

VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

Yahoo Top63 · neutralproduct/pr

Jul 21

VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)

InvestorsHub63 · neutralproduct/pr

Jul 21

VivoSim’s Breakthrough: First Commercial Sales in China Mark Significant Expansion for NAMkind Testing Platform July 21, 2026

MarketChameleon67 · bullishproduct/pr

Jul 21

VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

Business Insider63 · neutralproduct/pr

Jul 21

VivoSim Labs Announces $4 Million Private Placement Financing

TipRanks28 · bearishgeneral

Jul 17

Open VIVS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →